Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Research momentum at EASD 2026
From potential cure therapies and immune-targeting treatments to advances in technology, screening and psychological support, it was clear that real progress is being made across multiple areas of T1D research.
Research into insulin-producing (beta) cell replacement remained a major focus throughout the conference. Multiple research groups and companies presented updates on different approaches to restoring these cells and helping them survive in the body.
Some teams are exploring ways to create new beta cells from a person’s own cells, while others are developing cells designed to evade the immune attack. Researchers also continue to investigate how transplanted cells can be protected and supported once inside someone’s body.
Each approach comes with its own challenges, but together they represent important steps towards a future where people with T1D could once again produce their own insulin.
Another area generating excitement was immunotherapy research. Immunotherapies slow down the immune attack in T1D, delaying its progression and giving people more time without having to administer insulin.
Researchers shared updates on therapies designed to alter the immune processes involved in T1D, alongside updates from large international collaborations such as INNODIA. These studies are helping researchers better understand the disease and identify new opportunities for intervention.
The growing pipeline of immune therapies reflects a shift in T1D, from managing the condition after diagnosis towards delaying or changing its course.
Researchers also discussed ongoing efforts to identify T1D before symptoms develop.
Large screening programmes across Europe are demonstrating that population screening is both feasible and economically viable. International collaborations, including EDENT1FI and UK initiatives such as ELSA and T1DRA, continue to build evidence for earlier identification of T1D being a part of routine care. Beyond creating opportunities for earlier treatment, this work could help more people avoid serious complications at diagnosis and give families greater support and preparation.
The scale of these programmes reflects a growing international commitment to changing how T1D is diagnosed and managed.
Researchers presented their data on how advances in artificial intelligence, machine learning and automated insulin delivery systems could help make diabetes management simpler and more personalised.
Researchers are investigating technologies that better adapt to a person’s needs, including systems that account for factors such as hormone fluctuations and changing insulin requirements. Studies also highlighted progress towards fully closed-loop systems that require less user input, which could reduce some of the mental burden of living with T1D.
While many of these developments are still being tested, they point towards a future where diabetes technology can take on more of the workload.
Alongside scientific and technological advances, there was a strong recognition that living with T1D affects more than just physical health.
Mental wellbeing featured prominently at EASD 2026, including the publication of the first EASD Diabetes Distress Guidelines. Researchers also presented work exploring new ways to support people experiencing the emotional burden of diabetes, including digital tools designed to help manage diabetes distress.
This growing focus reflects an important shift in diabetes care: recognising that supporting emotional wellbeing is just as important as improving glucose management.
The research presented at EASD 2026 demonstrates that progress in T1D is happening on many fronts at once. Researchers are pursuing different research topics, from developing new therapies and improving technology to identifying T1D earlier and finding better ways to support mental wellbeing.
EASD showcased a global research effort that is steadily moving us closer to better treatments, prevention strategies and, ultimately, cures.
Find out how early detection works, why it matters, and how you can access screening for yourself, your child or someone you care for.
Dealing with type 1 every day can have an emotional impact, whether you’re newly diagnosed or have been living with type 1 for some time.
Find out about our research to find cures for T1D and make everyday life better for those who face it.
A new international position statement says people with diabetes should often be able to keep using continuous glucose monitors, insulin pumps and hybrid closed loop systems during a hospital stay, as long as it is safe and appropriate.
We look at a new feature coming to the CamAPS FX app, which will allow users to remove the need to count carbohydrates before a meal.
In draft guidance published today, NICE recommends that anyone with type 1 diabetes who is pregnant or planning a pregnancy should be offered pregnancy-specific HCL technology.
Discussing the main themes from this year's Advanced Technologies & Treatments for Diabetes conference – early detection, cellular cures and disease-modifying therapies.
Researchers from John Hopkins University, USA, partially funded by Breakthrough T1D, have developed an experimental treatment that protects the insulin-producing cells from inflammatory damage, allowing them to survive for longer in animal models.
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?
